Data from Multiple Phase I Trials Incorporating GenVec Technology Presented at International AIDS Conference; Safety and Immunogenicity Data Presented by NIH VRC and HVTN

Data from Multiple Phase I Trials Incorporating GenVec Technology Presented at International AIDS Conference; Safety and Immunogenicity Data Presented by NIH VRC and HVTN

Business Wire - August 31, 2006

GAITHERSBURG, Md. -- GenVec, Inc. (NASDAQ: GNVC) announced today that results from multiple Phase 1 clinical trials were presented at the AIDS Vaccine 2006 Conference in Amsterdam this week. The HIV vaccine incorporating GenVec's adenovector-based technology was well tolerated, and results were consistent with previously reported data: induction of potent immune responses when the vaccine was used alone or in combination with a DNA primer vaccine. The results support the rationale for advanced clinical testing.

In a study of the HIV vaccine incorporating GenVec's adenovector-based technology given to 40 volunteers as a single dose of either 1e10 Particle Units (PU) or 1e11 PU, both doses showed stimulation of T-cells against the multiple antigens contained in this vaccine. The study was presented by Dr. Larry Peiperl of University of California School of Medicine San Francisco, and the study was conducted by the HIV Vaccine Trials Network (HVTN).

In a second study presented by Dr. Richard Koup of the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, cellular immune responses were analyzed in 14 volunteers given a DNA prime followed by a boost with the HIV vaccine incorporating GenVec's adenovector technology. Dr. Koup reported that these data indicate that the combination of priming and boosting produces more polyfunctional T-cells than either modality alone. "Polyfunctional T-cells are a hallmark of existing vaccines such as the effective smallpox vaccine and are also believed to be important for an effective HIV vaccine. A similar breadth of polyfunctional T-cells occurs in patients who have HIV but do not progress rapidly to AIDS," commented Dr. Rick King, GenVec's Senior VP of Research.

In addition to the clinical presentations described above, there were presentations given by Drs. Gary Nabel and John Mascola of the VRC highlighting several next generation HIV vaccine approaches using GenVec adenovector technology.

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Additional information on GenVec and its portfolio of product candidates is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future programs and studies, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; the timing and content of future U.S. Food and Drug Administration regulatory actions with respect to GenVec, its product candidates, or collaborators, risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

CONTACT: GenVec, Inc.

Investor Relations:

Tricia J. Richardson, 240-632-5511 | trichardson@genvec.com

SOURCE: GenVec, Inc.

060831
BW060832

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .